These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 19780704

  • 21. Arsenic trioxide-induced apoptosis of Hep-2 cell line through modulating intracellular glutathione (GSH) level.
    Cheng B, Yang X, An L, Gao B, Liu X.
    Auris Nasus Larynx; 2010 Feb; 37(1):89-94. PubMed ID: 19574005
    [Abstract] [Full Text] [Related]

  • 22. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
    Hosein PJ, Craig MD, Tallman MS, Boccia RV, Hamilton BL, Lewis JJ, Lossos IS.
    Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459
    [No Abstract] [Full Text] [Related]

  • 23. [Arsenic efficient in acute promyelocytic leukemia].
    Lehmann S, Paul C.
    Lakartidningen; 1999 Dec 15; 96(50):5626-8. PubMed ID: 10643228
    [Abstract] [Full Text] [Related]

  • 24. Arsenic compounds: revived ancient remedies in the fight against human malignancies.
    Liu JX, Zhou GB, Chen SJ, Chen Z.
    Curr Opin Chem Biol; 2012 Apr 15; 16(1-2):92-8. PubMed ID: 22342767
    [Abstract] [Full Text] [Related]

  • 25. Cytotoxic Effects of Darinaparsin, a Novel Organic Arsenical, against Human Leukemia Cells.
    Yuan B, Kikuchi H, Li J, Kawabata A, Yao K, Takagi N, Okazaki M.
    Int J Mol Sci; 2023 Jan 23; 24(3):. PubMed ID: 36768603
    [Abstract] [Full Text] [Related]

  • 26. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E, Schultheis B, Büchner T, Hehlmann R.
    Dtsch Med Wochenschr; 2007 Feb 16; 132(7):330-6. PubMed ID: 17286223
    [No Abstract] [Full Text] [Related]

  • 27. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Kalmadi SR, Hussein MA.
    Acta Haematol; 2006 Feb 16; 116(1):1-7. PubMed ID: 16809883
    [Abstract] [Full Text] [Related]

  • 28. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P.
    J Biol Regul Homeost Agents; 1999 Feb 16; 13(4):195-200. PubMed ID: 10703942
    [Abstract] [Full Text] [Related]

  • 29. [Pharmacological profile and clinical study results of darinaparsin (DARVIAS® injection 135 ‍mg), an organic arsenic product, for relapsed or refractory peripheral t-cell lymphoma].
    Yao K, Sonehara Y, Nagahama F.
    Nihon Yakurigaku Zasshi; 2023 Feb 16; 158(5):408-418. PubMed ID: 37673618
    [Abstract] [Full Text] [Related]

  • 30. JWA is required for arsenic trioxide induced apoptosis in HeLa and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway.
    Zhou J, Ye J, Zhao X, Li A, Zhou J.
    Toxicol Appl Pharmacol; 2008 Jul 01; 230(1):33-40. PubMed ID: 18387645
    [Abstract] [Full Text] [Related]

  • 31. Clinical trials referral resource. Clinical trials with arsenic trioxide.
    Murgo AJ, McBee WL, Cheson BD.
    Oncology (Williston Park); 2000 Feb 01; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
    [No Abstract] [Full Text] [Related]

  • 32. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U.
    Leuk Res; 2007 Nov 01; 31(11):1585-7. PubMed ID: 17416415
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Sekeres MA.
    Curr Hematol Rep; 2005 Jan 01; 4(1):59-63. PubMed ID: 15610661
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
    Prescrire Int; 2004 Aug 01; 13(72):135-7. PubMed ID: 15532137
    [Abstract] [Full Text] [Related]

  • 37. The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent.
    Wu J, Shao Y, Liu J, Chen G, Ho PC.
    J Ethnopharmacol; 2011 Jun 01; 135(3):595-602. PubMed ID: 21497649
    [Abstract] [Full Text] [Related]

  • 38. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.
    Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A.
    Cancer Res; 2001 Jul 15; 61(14):5432-40. PubMed ID: 11454688
    [Abstract] [Full Text] [Related]

  • 39. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT, Pezzullo JC, Soignet SL.
    J Clin Oncol; 2003 Oct 01; 21(19):3609-15. PubMed ID: 14512391
    [Abstract] [Full Text] [Related]

  • 40. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
    Sumi D, Shinkai Y, Kumagai Y.
    Toxicol Appl Pharmacol; 2010 May 01; 244(3):385-92. PubMed ID: 20193703
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.